Salivary gland dysfunction ('dry mouth') in patients with cancer: A consensus statement

European Journal of Cancer Care

Volumn 19, Issue 2, 2010, Pages 172-177

  Davies, A ^a   Bagg, J ^b   Laverty, D ^c   Sweeney, P ^b   Filbet, M ^d   Newbold, K ^a   De Andres J ^e   Mercadante, S ^f  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^c Palliative Care   (United Kingdom)

^d CENTRE HOSPITALIER LYON SUD   (France)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f LA MADDALENA CANCER CENTER   (Italy)

Author keywords

Neoplasms; Salivary gland dysfunction; Salivary gland hypofunction; Xerostomia

Indexed keywords

CONSENSUS; CONSENSUS DEVELOPMENT; EVIDENCE BASED MEDICINE; HUMAN; NEOPLASM; REVIEW; SALIVARY GLAND DISEASE; XEROSTOMIA; COMPLICATION; NEOPLASMS; SALIVARY GLAND DISEASES;

CONSENSUS; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASMS; SALIVARY GLAND DISEASES; XEROSTOMIA;

EID: 76949108664     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2009.01081.x     Document Type: Review

References (39)

1. Amosson CM, Teh BS, Mai WY, Woo SY, Chiu JK, Donovan DT, Parke R, Carpenter LS, Lu HH, Grant WH, Butler EB. Using technology to decrease xerostomia for head and neck cancer patients treated with radiation therapy. Seminars in Oncology 2002, 29(19):71-79. Suppl.
2. Bäckström I, Funegård U, Andersson I, Franzén L, Johansson I. Dietary intake in head and neck irradiated patients with permanent dry mouth symptoms. European Journal of Cancer. Part B, Oral Oncology 1995, 31B:253-257.
3. Billings RJ, Proskin HM, Moss ME. Xerostomia and associated factors in a community-dwelling adult population. Community Dentistry and Oral Epidemiology 1996, 24:312-316.
4. Björnström M, Axéll T, Birkhed D. Comparison between saliva stimulants and saliva substitutes in patients with symptoms related to dry mouth. A multi-centre study. Swedish Dental Journal 1990, 14:53-61.
5. Chang VT, Hwang SS, Feuerman M, Kasimis BS, Thaler HT. The Memorial Symptom Assessment Scale Short Form (MSAS-SF). Cancer 2000, 89:1162-1171.
6. Chaushu G, Bercovici M, Dori S, Waller A, Taicher S, Kronenberg J, Talmi YP. Salivary flow and its relation with oral symptoms in terminally ill patients. Cancer 2000, 88:984-987.
7. Davies A. Salivary gland dysfunction. Oral Care in Advanced Disease 2005a, 97-113. Davies AFinlay I. In, eds, Oxford University Press, Oxford, UK
8. Davies A. Oral assessment. Oral Care in Advanced Disease 2005b, 7-19. Davies AFinlay I. In, eds, Oxford University Press, Oxford, UK
9. Davies A, Finlay I. Oral Care in Advanced Diseases 2005, eds, Oxford University Press, Oxford, UK
10. Davies AN, Shorthose K. Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database of Systematic Reviews 2007, 3. CD003782
11. Davies AN, Vriens J. Oral transmucosal fentanyl citrate and xerostomia. Journal of Pain and Symptom Management 2005, 30:496-497.
12. Davies AN, Broadley K, Beighton D. Xerostomia in patients with advanced cancer. Journal of Pain and Symptom Management 2001, 22:820-825.
13. Davies AN, Broadley K, Beighton D. Salivary gland hypofunction in patients with advanced cancer. Oral Oncology 2002, 38:680-685.
14. Davies AN, Brailsford SR, Beighton D. Oral candidosis in patients with advanced cancer. Oral Oncology 2006, 42:698-702.
15. Dirix P, Nuyts S, Vander Poorten V, Delaere P, Van den Bogaert W. The influence of xerostomia after radiotherapy on quality of life. Supportive Care in Cancer 2008, 16:171-179.
16. Folli F, Ponzoni M, Vicari AM. Paraneoplastic autoimmune xerostomia. Annals of Internal Medicine 1997, 127:167-168.
17. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001, 323:334-336.
18. Jensen SB, Pedersen AM, Reibel J, Nauntofte B. Xerostomia and hypofunction of the salivary glands in cancer therapy. Supportive Care in Cancer 2003, 11:207-225.
19. Jha N, Seikaly H, Harris J, Williams D, Liu R, McGaw T, Hofmann H, Robinson D, Hanson J, Barnaby P. Prevention of radiation induced xerostomia by surgical transfer of submandibular salivary gland into the submental space. Radiotherapy and Oncology 2003, 66:283-289.
20. Korsten MA, Rosman AS, Fishbein S, Shlein RD, Goldberg HE, Biener A. Chronic xerostomia increases esophageal acid exposure and is associated with esophageal injury. The American Journal of Medicine 1991, 90:701-706.
21. Leone CW, Oppenheim FG. Physical and chemical aspects of saliva as indicators of risk for dental caries in humans. Journal of Dental Education 2001, 65:1054-1062.
22. Nagler R, Marmary Y, Krausz Y, Chisin R, Markitziu A, Nagler A. Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD). Bone Marrow Transplantation 1996, 17:219-224.
23. Nagler RM, Gez E, Rubinov R, Laufer D, Ben-Aryeh H, Gaitini D, Filatov M, Kuten A. The effect of low-dose interleukin-2-based immunotherapy on salivary function and composition in patients with metastatic renal cell carcinoma. Archives of Oral Biology 2001, 46:487-493.
24. Navazesh M, Christensen C, Brightman V. Clinical criteria for the diagnosis of salivary gland hypofunction. Journal of Dental Research 1992, 71:1363-1369.
25. Nederfors T, Isaksson R, Mörnstad H, Dahlöf C. Prevalence of perceived symptoms of dry mouth in an adult Swedish population - relation to age, sex and pharmacotherapy. Community Dentistry and Oral Epidemiology 1997, 25:211-216.
26. Pankhurst CL, Smith EC, Rogers JO, Dunne SM, Jackson SHD, Proctor G. Diagnosis and management of the dry mouth: Part 1. Dental Update 1996a, 23:56-62.
27. Pankhurst CL, Dunne SM, Rogers JO. Restorative dentistry in the patient with dry mouth: part 2. Problems and solutions. Dental Update 1996b, 23:110-114.
28. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Coyle N, Smart-Curley T, Kemeny N, Norton L, Hoskins W, Scher H. Symptom prevalence, characteristics and distress in a cancer population. Quality of Life Research 1994, 3:183-189.
29. Rydholm M, Strang P. Physical and psychosocial impact of xerostomia in palliative cancer care: a qualitative interview study. International Journal of Palliative Nursing 2002, 8:318-323.
30. Sasse AD, Clark LG, Sasse EC, Clark OA. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. International Journal of Radiation Oncology, Biology, Physics 2006, 64:784-791.
31. Schubert MM, Izutsu KT. Iatrogenic causes of salivary gland dysfunction. Journal of Dental Research 1987, 66:680-688. Spec Iss
32. Senn HJ. Orphan topics in supportive care: how about xerostomia? Supportive Care in Cancer 1997, 5:261-262.
33. Shorthose K, Andrew ND. Symptom prevalence in palliative care. Palliative Medicine 2003, 17:723-724.
34. Solans R, Bosch JA, Galofré P, Porta F, Roselló J, Selva-O'Callagan A, Vilardell M. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. Journal of Nuclear Medicine 2001, 42:738-743.
35. Sreebny LM. Xerostomia: diagnosis, management and clinical complications. Saliva and Oral Health 1996, 43-66. Edgar WMO'Mullane DM. In, 2nd, edn (eds, British Dental Association, London, UK
36. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth - 2nd edn. Gerodontology 1997, 14:33-47.
37. Sreebny LM, Valdini A. Xerostomia. Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surgery, Oral Medicine, and Oral Pathology 1988, 66:451-458.
38. Sweeney P. Oral hygiene. Oral Care in Advanced Disease 2005, 21-35. Davies AFinlay I. In, eds, Oxford University Press, Oxford, UK
39. Tranmer JE, Heyland D, Dudgeon D, Groll D, Squires-Graham M, Coulson K. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the Memorial Symptom Assessment Scale. Journal of Pain and Symptom Management 2003, 25:420-429.